header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

Knee

CLINICAL OUTCOME EVALUATION OF INTRAOSSEUS VANCOMYCIN IN TOTAL KNEE ARTHROPLASTY

The Knee Society (TKS) 2019 Members Meeting, Cape Neddick, ME, USA, 5–7 September 2019.



Abstract

Introduction

Vancomycin is a prophylactic antibiotic used to protect against methicillin resistant staph aureus. Recent literature has suggested that using intraosseus (IO) infusions are capable of providing improved local tissue concentrations compared to intravenous (IV) access. The purpose of this study is to evaluate clinical outcomes of patients who received pre-operative IO vancomycin for total knee arthroplasty (TKA).

Methods

Patients who received IO vancomycin (500mg vancomycin in 200ml NS) as standard of care from September 1, 2018 to March 1, 2019 were retrospectively evaluated. This data was compared to primary and revision TKAs performed immediately prior to the initiation of IO administration. Evaluation included pre and post-op creatinine values, tourniquet time (TT), and knee-related 30 and 90-day complications. Data for primary and revision TKA cases were analyzed independently.

Results

Final analysis had 100 primaries and 29 revisions in the control (IV) and 100 primaries and 19 revisions in the intervention (IO) arm. 30 and 90-day complications were not significantly different in primaries, while decreased 30–day complications for revisions approached significance (control=17.2%, intervention=10.5%). 90-day complications were decreased in the revision group receiving IO (Control=27.6%, Intervention = 0%; p=0.015). No cases of Redman Syndrome were identified. No increase in post-operative creatinine values occurred. TT was increased by 1.87min in the PI, which was not statistically significant (p=0.10).

Discussion / Conclusion

We've demonstrated IO vancomycin is a safe and effective alternative to using pre-operative IV vancomycin. This is one of the largest series to date evaluating the clinical outcomes while using IO antibiotics pre-operatively in TKA. Patients who receive IO vancomycin have equivalent or improved 30 and 90-day complication rates, significantly so in revision TKAs. In addition, this study evaluated longer-term outcomes of revision TKAs that are provided IO vancomycin, proving it may be appropriate to extend indications.

For figures, tables, or references, please contact authors directly.